The Norwegian weight loss market is witnessing a significant shift as American pharmaceutical giant Eli Lilly introduces its new drug, Mounjaro, to compete with the Danish company Novo Nordisk's popular Wegovy.

Mounjaro, which will be available in Norway from November 1st, is touted to be more effective due to its dual-action on hunger hormones.

This new entrant is expected to intensify competition, potentially leading to price reductions, a hope expressed by experts like Jøran Hjelmesæth.

However, concerns remain about the high costs of these medications, which are not yet covered by the state, creating a disparity in access.

While Mounjaro offers a promising alternative, experts caution about the unknown long-term effects and emphasize the importance of lifestyle changes alongside medication.